article thumbnail

New podcast on the future for genomics and big data

Drug Discovery World

This is the latest episode of the free DDW narrated podcast, “What lies in the future for genomics and big data?”, They are called “ What’s the next step in big data and AI? ” and “ Why a recent advancement is a giant leap for human genomics ”.

article thumbnail

Recognizing the Real People Behind the Big Data and Artificial Intelligence in Clinical Research

ACRP blog

If you hadn’t already noticed, the clinical research enterprise has well and truly entered the era of “big data,” artificial intelligence (AI), and machine learning. Undoubtedly, the expectations for precision medicine are high,” Olsen adds.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Big data – charting a new path to drug discovery and development

Drug Discovery World

Drug discovery and development timelines can span 10-15 years or more from initial discovery to market approval and typically require the analysis of massive amounts of data. Nonetheless, AI and ML are expected to play a more significant role in bioprocessing as plants are updated.

article thumbnail

Digitalising drug discovery

pharmaphorum

As data and digital technology become vital to every aspect of life sciences, the industry is increasingly looking beyond biologists, chemists, and doctors to drive its drug development – and finding that technology has a chief role to play in the future of medicine. on Big data: astronomical or genomical? ,

article thumbnail

Takeda, Daiichi-backed wearable study planned in Japan

pharmaphorum

The results generated in the study will be combined with data from Tohoku’s Medical Megabank Project (TMM), a wide-ranging national project that is tracking the health of the Japanese population, originally set up in response to the 2011 earthquake and tsunami.

article thumbnail

Medical Informatics: a bridge between two worlds

pharmaphorum

Thus, she belongs to the Center for Medical Informatics at the University Medicine Dresden. Her research area is the secondary use of observational data of patients with rare and unclear diseases; with attention to the research data infrastructure and terminologies.

Genome 78
article thumbnail

The future of AI drug discovery & development in immunology and GPCR research

pharmaphorum

Essentially, the collaboration brought together both “the right expertise and the right technology”, opening up myriad possibilities for targeting GPCRs within the human genome. Kim recognised then, he said, that better tools for medicine needed to be developed, and that they still do. What, then, is the solution?